PTC Therapeutics Welcomes Jessica Chutter to Board of Directors, a Move for Future Growth

PTC Therapeutics Welcomes Jessica Chutter to its Board of Directors

PTC Therapeutics, Inc., a prominent player in the biopharmaceutical industry, has recently appointed Jessica Chutter to its Board of Directors. This strategic move is set to enhance the company's governance and guide its future endeavors. Ms. Chutter brings over four decades of invaluable experience in biotechnology investment banking, specifically from her tenure at Morgan Stanley.

A Trailblazer in Biotech Banking

Jessica Chutter has a remarkable background, having played a pivotal role in establishing the biotechnology franchise at Morgan Stanley. Her career is characterized by a significant impact on the biotechnology sector, evidenced by her involvement in raising approximately $80 billion in capital and facilitating $85 billion in strategic transactions. Chutter's impressive academic credentials include a BA in Commerce/Economics from McGill University and an MBA from Harvard University.

Looking Ahead with Confidence

Michael Schmertzler, Chairman of the Board of Directors at PTC Therapeutics, expressed enthusiasm about Chutter's appointment, stating, "I have closely followed Jessica's illustrious career, and I am proud to welcome her to PTC's Board of Directors." He believes her extensive capabilities will be crucial as the Board collaborates with management in steering the company towards its next phase of growth.

Matthew B. Klein, M.D., CEO of PTC Therapeutics, echoed these sentiments, highlighting Chutter’s prior role as a trusted advisor during her time at Morgan Stanley. He conveyed optimism about her contributions as PTC moves forward, underscoring her visionary outlook and proven track record in successful company development.

Jessica Chutter's Vision

Upon her appointment, Ms. Chutter noted the transformation PTC has undergone over the past few years, asserting her excitement about contributing to the company's success. "I have been impressed with the transformation of PTC over the past few years into a strong and execution-oriented biotech company well positioned for future success,” she stated. Chutter expressed her eagerness to work closely with the PTC team during this pivotal time in the company's trajectory.

About PTC Therapeutics

PTC Therapeutics is a global biopharmaceutical organization committed to discovering, developing, and commercializing innovative medicines for individuals living with rare disorders. Their robust, diversified pipeline is dedicated to delivering transformative treatments tailored to patients' unmet medical needs. By leveraging their scientific expertise alongside a strong global infrastructure, PTC aims to optimize value for stakeholders and, most importantly, the patients they serve.

For further information about PTC Therapeutics and their future developments, visit PTC's official website. Stay connected with the company’s updates on their social media platforms, including LinkedIn, Twitter, Instagram, and Facebook.

This appointment signifies not just a strengthening of PTC’s Board, but also a bold step towards enhancing its strategic ambitions in the biopharmaceutical landscape. As Jessica Chutter joins the ranks, the biotech company looks poised for further success, pushing the boundaries of innovation in rare disease treatments.